The prevalence of thyroid disease in patients with vitiligo: A systematic review

British Journal of Dermatology

Volumn 167, Issue 6, 2012, Pages 1224-1235

  Vrijman, C ^a   Kroon, M W ^a   Limpens, J ^a   Leeflang, M M G ^a   Luiten, R M ^a   Van Der Veen, J P W ^a,b   Wolkerstorfer, A ^a   Spuls, P I ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EMBASE; HUMAN; MEDLINE; META ANALYSIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK; SYSTEMATIC REVIEW; THYROID DISEASE; VITILIGO;

AGE FACTORS; ANTIBODIES; AUTOANTIBODIES; HUMANS; PREVALENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; THYROID DISEASES; VITILIGO;

EID: 84870249060     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11198.x     Document Type: Review

References (74)

1. Lerner AB,. Vitiligo. J Invest Dermatol 1959; 32: 285-310.
2. Alikhan A, Felsten LM, Daly M, et al. Vitiligo: a comprehensive overview. Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol 2011; 65: 473-91.
3. Barona MI, Arrunategui A, Falabella R, et al. An epidemiologic case-control study in a population with vitiligo. J Am Acad Dermatol 1995; 33: 621-5.
4. van Geel NA, Mollet IG, De Schepper S, et al. First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi. Pigment Cell Melanoma Res 2010; 23: 375-84.
5. van Geel N, Mollet I, Brochez L, et al. New insights in segmental vitiligo: case report and review of theories. Br J Dermatol 2012; 166: 240-6.
6. Spritz RA,. The genetics of vitiligo. J Invest Dermatol 2011; 131: E18-20.
7. van den Boorn JG, Konijnenberg D, Dellemijn TA, et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 2009; 129: 2220-32.
8. Jin Y, Birlea SA, Fain PR, et al. Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N Engl J Med 2010; 362: 1686-97.
9. Jin Y, Birlea SA, Fain PR, et al. Common variants in FOXP1 are associated with generalized vitiligo. Nat Genet 2010; 42: 576-8.
10. Laberge G, Mailloux CM, Gowan K, et al. Early disease onset and increased risk of other autoimmune diseases in familial generalized vitiligo. Pigment Cell Res 2005; 18: 300-5.
11. Spritz RA,. Shared genetic relationships underlying generalized vitiligo and autoimmune thyroid disease. Thyroid 2010; 20: 745-54.
12. Hegedus L, Heidenheim M, Gervil M, et al. High frequency of thyroid dysfunction in patients with vitiligo. Acta Derm Venereol (Stockh) 1994; 74: 120-3.
13. Betterle C, Caretto A, De Zio A, et al. Incidence and significance of organ-specific autoimmune disorders (clinical, latent or only autoantibodies) in patients with vitiligo. Dermatologica 1985; 171: 419-23.
14. Iacovelli P, Sinagra JL, Vidolin AP, et al. Relevance of thyroiditis and of other autoimmune diseases in children with vitiligo. Dermatology 2005; 210: 26-30.
15. Kakourou T, Kanaka-Gantenbein C, Papadopoulou A, et al. Increased prevalence of chronic autoimmune (Hashimoto's) thyroiditis in children and adolescents with vitiligo. J Am Acad Dermatol 2005; 53: 220-3.
16. Kurtev A, Dourmishev AL,. Thyroid function and autoimmunity in children and adolescents with vitiligo. J Eur Acad Dermatol Venereol 2004; 18: 109-11.
17. Surks MI, Hollowell JG,. Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol Metab 2007; 92: 4575-82.
18. Daneshpazhooh M, Mostofizadeh GM, Behjati J, et al. Anti-thyroid peroxidase antibody and vitiligo: a controlled study. BMC Dermatol 2006; 6: 3.
19. Hutfless S, Matos P, Talor MV, et al. Significance of prediagnostic thyroid antibodies in women with autoimmune thyroid disease. J Clin Endocrinol Metab 2011; 96: E1466-71.
20. Scofield RH,. Autoantibodies as predictors of disease. Lancet 2004; 363: 1544-6.
21. Shong YK, Kim JA,. Vitiligo in autoimmune thyroid disease. Thyroidology 1991; 3: 89-91.
22. Uncu S, Yayli S, Bahadir S, et al. Relevance of autoimmune thyroiditis in children and adolescents with vitiligo. Int J Dermatol 2011; 50: 175-9.
23. Gawkrodger DJ, Ormerod AD, Shaw L, et al. Guideline for the diagnosis and management of vitiligo. Br J Dermatol 2008; 159: 1051-76.
24. Menke HE, van Everdingen JJE, van Geel NAC, et al. Richtlijn Vitiligo. Utrecht: Nederlandse Vereniging voor Dermatologie en Venereologie en Kwaliteitsinstituut voor de Gezondheidszorg CBO, 2006.
25. Loney PL, Chambers LW, Bennett KJ, et al. Critical appraisal of the health research literature: prevalence or incidence of a health problem. Chronic Dis Can 1998; 19: 170-6.
26. Radulescu M, Diepgen T, Williams HC,. What makes a good prevalence survey? In: Evidence-Based Dermatology (, Williams HC, Bigby M, Diepgen T, Herxheimer A, Naldi L, Rzany B, eds), 2nd edn. Oxford: Blackwell Publishing, 2008; 61-7.
27. The Cochrane Collaboration. Review Manager (RevMan), Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
28. Arora NVK, Shankar V, Chaudhary SD, Nagpal RK,. Triiodothyronine, thyroxine and thyrotropin levels in vitiligo. Indian J Dermatol Venereol Leprol 1990; 56: 299-300.
29. Frati R, Frati C, Sassano PP, et al. Vitiligo, autoimmune thyroiditis: a rare thyroid cancer arising with bone metastates on maxillofacial area. J Exp Clin Cancer Res 1999; 18: 85-7.
30. Kasumagic-Halilovic E, Prohic A, Begovic B, et al. Association between vitiligo and thyroid autoimmunity. J Thyroid Res 2011; 2011: 938257.
31. Mandry RC, Ortiz LJ, Lugo-Somolinos A, et al. Organ-specific autoantibodies in vitiligo patients and their relatives. Int J Dermatol 1996; 35: 18-21.
32. Rose NR,. Prediction and prevention of autoimmune disease: a personal perspective. Ann N Y Acad Sci 2007; 1109: 117-28.
33. Boucai L, Hollowell JG, Surks MI,. An approach for development of age-, gender-, and ethnicity-specific thyrotropin reference limits. Thyroid 2011; 21: 5-11.
34. Jacobson DL, Gange SJ, Rose NR, et al. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997; 84: 223-43.
35. Kemp EH,. Autoantibodies as diagnostic and predictive markers of vitiligo. Autoimmunity 2004; 37: 287-90.
36. Nordyke RA, Gilbert FI Jr, Miyamoto LA, et al. The superiority of antimicrosomal over antithyroglobulin antibodies for detecting Hashimoto's thyroiditis. Arch Intern Med 1993; 153: 862-5.
37. Kroon MW, Joore IC, Wind BS, et al. Low yield of routine screening for thyroid dysfunction in asymptomatic patients with vitiligo. Br J Dermatol 2012; 166: 532-8.
38. Akay BN, Bozkir M, Anadolu Y, et al. Epidemiology of vitiligo, associated autoimmune diseases and audiological abnormalities: Ankara study of 80 patients in Turkey. J Eur Acad Dermatol Venereol 2010; 24: 1144-50.
39. Al-Jabri MM, Al-Raddadi A,. Childhood vitiligo: a retrospective hospital based study, Jeddah, Saudi Arabia. J Saudi Soc Dermatol Dermatolog Surg 2011; 15: 15-17.
40. Al-Mutairi N, Sharma AK, Al-Sheltawy M, et al. Childhood vitiligo: a prospective hospital-based study. Australas J Dermatol 2005; 46: 150-3.
41. Amerio P, Di Rollo D, Carbone A, et al. Polyglandular autoimmune diseases in a dermatological clinical setting: vitiligo-associated autoimmune diseases. Eur J Dermatol 2010; 20: 354-8.
42. Arycan O, Koc K, Ersoy L,. Clinical characteristics in 113 Turkish vitiligo patients. Acta Dermatovenerol Alp Panonica Adriat 2008; 17: 129-32.
43. Birlea SA, Fain PR, Spritz RA,. A Romanian population isolate with high frequency of vitiligo and associated autoimmune diseases. Arch Dermatol 2008; 144: 310-16.
44. Brostoff J,. Autoantibodies in patients with vitiligo. Lancet 1969; ii: 177-8.
45. Cho SB, Kim JH, Cho S, et al. Vitiligo in children and adolescents: association with thyroid dysfunction. J Eur Acad Dermatol Venereol 2011; 25: 64-7.
46. Cunliffe WJ, Hall R, Newell DJ, et al. Vitiligo, thyroid disease and autoimmunity. Br J Dermatol 1968; 80: 135-9.
47. Doutre M-S, Beylot C, Latapie JL,. Thyroid auto-antibodies in vitiligo and alopecia areata. 120 cases. Rev Fr Endocrinol Clin 1985; 26: 577-9.
48. Gonul M, Cakmak SK, Oguz D, et al. Profile of vitiligo patients attending a training and research hospital in Central Anatolia: a retrospective study. J Dermatol 2012; 39: 156-9.
49. Gopal KV, Rama Rao GR, Kumar YH, et al. Vitiligo: a part of a systemic autoimmune process. Indian J Dermatol Venereol Leprol 2007; 73: 162-5.
50. Grimes PE, Halder RM, Jones C, et al. Autoantibodies and their clinical significance in a black vitiligo population. Arch Dermatol 1983; 119: 300-3.
51. Ingordo V, Gentile C, Iannazzone SS, et al. Vitiligo and autoimmunity: an epidemiological study in a representative sample of young Italian males. J Eur Acad Dermatol Venereol 2011; 25: 105-9.
52. Karelson M, Silm H, Salum T, et al. Differences between familial and sporadic cases of vitiligo. J Eur Acad Dermatol Venereol 2012; 26: 915-18.
53. Korkij W, Soltani K, Simjee S, et al. Tissue-specific autoantibodies and autoimmune disorders in vitiligo and alopecia areata: a retrospective study. J Cutan Pathol 1984; 11: 522-30.
54. Kumar KV, Priya S, Sharma R, et al. Autoimmune thyroid disease in patients with vitiligo: prevalence study from India. Endocr Pract 2012; 18: 194-9.
55. Martis J, Bhat R, Nandakishore B, et al. A clinical study of vitiligo. Indian J Dermatol Venereol Leprol 2002; 68: 92-3.
56. Mazereeuw-Hautier J, Bezio S, Mahe E, et al. Segmental and nonsegmental childhood vitiligo has distinct clinical characteristics: a prospective observational study. J Am Acad Dermatol 2010; 62: 945-9.
57. Miklaszewska M, Zukowski W, Dankiewicz J, et al. Clinical and immunologic aspects of the relation of acquired leukoderma (vitiligo) to thyroid diseases. Arch Immunol Ther Exp (Warsz) 1972; 20: 885-92.
58. Nunes DH, Esser LM,. Vitiligo epidemiological profile and the association with thyroid disease. An Bras Dermatol 2011; 86: 241-8.
59. Pagovich OE, Silverberg JI, Freilich E, et al. Thyroid abnormalities in pediatric patients with vitiligo in New York City. Cutis 2008; 81: 463-6.
60. Paravar T, Lee DJ,. Vitiligo in an urban academic setting. Int J Dermatol 2010; 49: 39-43.
61. Sedighe M, Gholamhossein G,. Thyroid dysfunction and thyroid antibodies in Iranian patients with vitiligo. Indian J Dermatol 2008; 53: 9-11.
62. Schallreuter KU, Lemke R, Brandt O, et al. Vitiligo and other diseases: coexistence or true association? Hamburg study on 321 patients. Dermatology 1994; 188: 269-75.
63. Tanioka M, Yamamoto Y, Katoh M, et al. Vitiligo vulgaris and autoimmune diseases in Japan: a report from vitiligo clinic in Kyoto University Hospital. Dermatoendocrinology 2009; 1: 43-5.
64. Yang Y, Lin X, Fu W, et al. An approach to the correlation between vitiligo and autoimmune thyroiditis in Chinese children. Clin Exp Dermatol 2010; 35: 706-10.
65. Zettinig G, Tanew A, Fischer G, et al. Autoimmune diseases in vitiligo: do anti-nuclear antibodies decrease thyroid volume? Clin Exp Immunol 2003; 131: 347-54.
66. Alkhateeb A, Fain PR, Thody A, et al. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res 2003; 16: 208-14.
67. Boisseau-Garsaud AM, Garsaud P, Cales-Quist D, et al. Epidemiology of vitiligo in the French West Indies (Isle of Martinique). Int J Dermatol 2000; 39: 18-20.
68. Ezzedine K, Diallo A, Leaute-Labreze C, et al. Multivariate analysis of factors associated with early-onset segmental and nonsegmental vitiligo: a prospective observational study of 213 patients. Br J Dermatol 2011; 165: 44-9.
69. Handa S, Kaur I,. Vitiligo: clinical findings in 1436 patients. J Dermatol 1999; 26: 653-7.
70. Handa S, Dogra S,. Epidemiology of childhood vitiligo: a study of 625 patients from north India. Pediatr Dermatol 2003; 20: 207-10.
71. Mason CP, Gawkrodger DJ,. Vitiligo presentation in adults. Clin Exp Dermatol 2005; 30: 344-5.
72. Narita T, Oiso N, Fukai K, et al. Generalized vitiligo and associated autoimmune diseases in Japanese patients and their families. Allergol Int 2011; 60: 505-8.
73. Nicolaidou E, Antoniou C, Miniati A, et al. Childhood- and later-onset vitiligo have diverse epidemiologic and clinical characteristics. J Am Acad Dermatol 2012; 66: 954-8.
74. Onunu AN, Kubeyinje EP,. Vitiligo in the Nigerian African: a study of 351 patients in Benin City, Nigeria. Int J Dermatol 2003; 42: 800-2.